Asahi Intecc has been granted a patent for a device that enhances the delivery of a composition to a patient’s body region using modulated radiofrequency energy. The device features a composition delivery element and electrodes that generate an electric field to improve delivery efficacy. GlobalData’s report on Asahi Intecc gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Asahi Intecc, Shapeable guide catheters was a key innovation area identified from patents. Asahi Intecc's grant share as of July 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
Enhanced delivery of compositions using radiofrequency energy
The granted patent US12059544B2 describes a novel device designed to enhance the delivery of therapeutic compositions to specific body regions of patients through the application of radiofrequency energy. The device features a first longitudinal member with a proximal and distal end, incorporating at least one lumen that extends between these ends. At the distal end, a composition delivery device is positioned, which contains the therapeutic composition on its outer surface. The device is equipped with at least two electrodes that are integrated within the composition delivery device and are connected to a radiofrequency source. These electrodes are insulated to create an electric field that facilitates the enhanced delivery of the composition. Notably, the radiofrequency energy is delivered in modulated pulses, with the timing of these pulses being controlled by a waveform signal derived from the patient's body.
Further specifications of the device include the option for the composition delivery device to take the form of a balloon, which may feature a porous surface to optimize the delivery process. The electrodes can also serve as markers on the balloon, aiding in positioning and monitoring during use. The compositions intended for delivery can include a range of therapeutic agents or pharmaceutical compounds, such as thrombolytic agents, fibrinolytic enzymes, thrombin inhibitors, antiplatelet agents, anticoagulants, anti-restenotic agents, or anti-cancer agents. This innovative approach aims to improve the efficacy of treatment by ensuring that therapeutic agents are delivered more effectively to targeted areas within the body.
To know more about GlobalData’s detailed insights on Asahi Intecc, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
